Gutmann R, Mees K
Klinik und Poliklinik für Hals-, Nasen- und Ohrenkranke, Ludwig-Maximilians-Universität München.
Fortschr Med. 1995 Jun 30;113(18):288-90.
In a prospective randomised clinical study on 39 patients with tinnitus and sudden hearing loss the therapeutic efficacy of piracetam/HAES 6% was compared with that of naftidrofuryl/HAES 6%. The two groups of patients were comparable in terms of demographic and audiological baseline data. The parameters evaluated were hearing improvement and the reduction in intensity of tinnitus. Improvement in hearing was 15 dB (piracetam) versus 18.5 dB (naftidrofuryl). The improvement in tinnitus amounted 27 dB (piracetam) and 19.9 dB (naftidrofuryl). Both differences were not significant. Tolerability was very good in both groups. Piracetam, which improves rheology and has a positive effect on metabolism, would appear of particular interest for the treatment of acute tinnitus.
在一项针对39例耳鸣伴突发性听力损失患者的前瞻性随机临床研究中，比较了吡拉西坦/6%羟乙基淀粉与萘呋胺酯/6%羟乙基淀粉的治疗效果。两组患者在人口统计学和听力学基线数据方面具有可比性。评估的参数为听力改善情况和耳鸣强度降低情况。听力改善方面，吡拉西坦组为15分贝，萘呋胺酯组为18.5分贝。耳鸣改善方面，吡拉西坦组为27分贝，萘呋胺酯组为19.9分贝。两者差异均无统计学意义。两组的耐受性都非常好。吡拉西坦可改善流变学并对新陈代谢有积极作用，似乎对急性耳鸣的治疗特别有意义。
